application abstract) This application is for renewed funding of the Howard University ACTU to: a) continue the ACTU at Howard University; b) expand the AIDS Clinical Trials efforts started under the ACTUs at Minority Institutions cooperative agreement funded by NIAID; c) promote minorities participation in AIDS clinical trials; d) conduct ACTG-sponsored research of mutual interest and importance to minorities and the ACTG; and e) explore with the NIAID the feasibility of conducting special studies relevant to minorities, e.g., low-dose oral alpha interferon. Clinical trials will encompass all stages of therapeutic evaluation, with emphasis on phase II (continuing safety/initial efficacy studies) and phase III (definitive efficacy studies). The investigators propose to assist in the development of protocols, recruit patients with HIV infection, coordinate data and specimen collection, maintain quality control of data entry, and collaborate with NIAID and other institutions in ACTG trials. In order to facilitate the recruitment of minorities, the staff includes an outreach worker, and a Hispanic social worker to target the African- American and Hispanic communities, respectively. The overall composition of the staff is intended to reflect the minority populations targeted. Patients will be recruited from hospital clinics, private physicians, and community-based clinics and organizations. Laboratory services will be provided by the Maryland Medical Metpath Laboratory, an ACTG-approved laboratory. Given the available resources at the institution and the population served, the proposed studies emphasize trials of therapies for HIV disease and opportunistic infections. In addition to ongoing studies including ACTG 177, 186 169, 222, 175, 242, and 193A, the investigators plan to add ACTG 260, 261, 277, 223, 251, and 272. The proposed studies will be conducted at the research clinic, which is located directly across the street from Howard University Hospital. The ACTU anticipates enrolling a minimum of 75 patients per year and proposes to increase the present staff by adding a part-time data entry clerk.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI034835-07
Application #
2856017
Study Section
Special Emphasis Panel (SRC (30))
Program Officer
Batzold, Frederick
Project Start
1993-09-01
Project End
2004-12-31
Budget Start
1999-01-01
Budget End
2004-12-31
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Howard University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
056282296
City
Washington
State
DC
Country
United States
Zip Code
20059
Leger, Paul D; Johnson, Daniel H; Robbins, Gregory K et al. (2014) Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J Neurovirol 20:304-8
Kiezun, Adam; Garimella, Kiran; Do, Ron et al. (2012) Exome sequencing and the genetic basis of complex traits. Nat Genet 44:623-30
McLaren, Paul J; Ripke, Stephan; Pelak, Kimberly et al. (2012) Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet 21:4334-47
Pasaniuc, Bogdan; Rohland, Nadin; McLaren, Paul J et al. (2012) Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet 44:631-5
Hulgan, Todd; Robbins, Gregory K; Kalams, Spyros A et al. (2012) T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384. PLoS One 7:e43803
Ribaudo, Heather J; Benson, Constance A; Zheng, Yu et al. (2011) No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 52:929-40
Grady, Benjamin J; Samuels, David C; Robbins, Gregory K et al. (2011) Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. J Acquir Immune Defic Syndr 58:363-70
Grady, Benjamin J; Torstenson, Eric S; McLaren, Paul J et al. (2011) Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pac Symp Biocomput :253-64
Cohn, Susan E; Jiang, Hongyu; McCutchan, J Allen et al. (2011) Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care 23:775-85
International HIV Controllers Study (see original citation for additional authors) (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-7

Showing the most recent 10 out of 13 publications